BiotechTube
Isabi

Isabi

San Francisco, United States· Est.
isabl.io
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Isabl is a private, pre-revenue diagnostics company developing a comprehensive whole-genome and transcriptome sequencing (WGTS) platform for cancer. Its proprietary Isabl GxT technology, which has received FDA Breakthrough Device Designation, aims to replace limited gene panels by analyzing the entire tumor genome and transcriptome to identify all classes of clinically relevant biomarkers from a single biopsy. Spun out from Memorial Sloan Kettering Cancer Center in 2020, the company is backed by notable investors including Two Sigma Ventures and Y Combinator and is preparing for a Research Use Only (RUO) release of its test in 2024 while pursuing clinical partnerships.

Oncology

Technology Platform

Proprietary whole-genome and transcriptome sequencing (WGTS) platform (Isabl GxT) that analyzes 100% of tumor DNA, germline DNA, and RNA from a single biopsy to detect all classes of cancer-associated mutations and biomarkers.

Opportunities

The growing demand for comprehensive precision oncology diagnostics creates a large market for a single test that can replace multiple limited panels.
The platform's ability to uncover novel biomarkers also presents a major opportunity in pharmaceutical R&D for patient stratification and drug development.

Risk Factors

Key risks include the challenge of securing insurance reimbursement for a comprehensive, likely higher-cost test, the need to demonstrate clear clinical utility over established panel tests to drive adoption, and navigating the complex regulatory pathway to FDA approval despite Breakthrough Device status.

Competitive Landscape

Isabl competes with established comprehensive genomic profiling companies like Foundation Medicine (Roche), Guardant Health, and Tempus, which currently dominate with large (300-500 gene) panels. Its whole-genome approach is a technological differentiator but must prove superior clinical value to overcome entrenched competitors and justify potential workflow changes.

More companies in Diagnostics & Precision Medicine →More companies in United States →